Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives
We have big plans across our B2C and B2B businesses in India and abroad
Standalone profit from operations for Q4-2024 were Rs. 108 crore
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
This will lead to the consolidation and optimization of the company's operations related to the manufacturing of ampoules and vials
The observations issued are neither repeated observations nor related to data integrity
Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure
USFDA inspection at Emcure Pharmaceuticals API facility
This is Senores' second API manufacturing facility adding significantly to the existing API manufacturing capabilities.
This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.
Subscribe To Our Newsletter & Stay Updated
